Mezlocillin and carbenicillin: a clinical comparison of serious systemic infections in surgical patients.
Eighty patients suffering from severe cases of systemic surgical infections were enrolled in a prospective, controlled randomized study to compare mezlocillin and carbenicillin. The daily dosage was chosen according to international recommendation, i.e. 4 g mezlocillin 6-hourly and 5 g carbenicillin 4-hourly. A clinical, bacteriological and combined "overall" evaluation was made. There was a distinct trend in favour of the mezlocillin group which was not statistically significant. The treatment was well tolerated; no side-effects were observed.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002228:Carbenicillin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008802:Mezlocillin; D010406:Penicillins / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy; D011446:Prospective Studies; D011897:Random Allocation; D013530:Surgical Wound Infection / Q000188:drug therapy*
D010406:Penicillins; D002228:Carbenicillin; D008802:Mezlocillin